Technology Development for Physical Rehabilitation of Patients With Upper Extremity Motor Deficits (RePlay)

Spinal Cord Injuries Clinical Trial

— RePlay  

Official title:

Technology Development for Physical Rehabilitation of Patients With Upper Extremity Motor Deficits

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03621969
• Other study ID #: 16-74
• Status: Completed
• Phase: N/A
• Start date: October 10, 2017
• Est. completion date: April 30, 2018

Study information

• Verified date: February 2023
• Source: The University of Texas at Dallas
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Injuries and disease processes that produce upper extremity deficits are devastating to patients and their families. One potential avenue to treat these neurological disorders is through the enhancement of neural plasticity, which is the ability of the brain to reorganize and recover following insult. After a minor injury, the brain undergoes beneficial neural plasticity, compensating for altered neural activity to restore normal function. However, in the cases of moderate to severe injury and disease, e.g. spinal cord injury (SCI), insufficient or improper plasticity limits recovery, leaving patients with long-term disability. Therefore, methods that can drive robust and specific plasticity have great potential to treat neurological injuries and disease.

The Texas Biomedical Device Center (TXBDC) at UT Dallas has developed a groundbreaking therapy, called Targeted Plasticity Therapy (TPT), which pairs traditional motor, sensory, and cognitive rehabilitation with precise stimulation of the vagus nerve, to guide such robust and specific plasticity to treat a wide range of neurological deficits.

Description:

The groundbreaking therapy developed at Texas Biomedical Device Center (TXBDC) , called Targeted Plasticity Therapy (TPT) pairs traditional motor, sensory, and cognitive rehabilitation with precise stimulation of the vagus nerve, to guide such robust and specific plasticity to treat a wide range of neurological deficits. The success of this concomitant therapy will be furthered, in part, through the development and use of mechanical devices aimed at measuring the effects of rehabilitation in patients with an upper extremity neurological deficit, e.g. from SCI. These devices are small hand controllers used to play simple video games that can also measure force and movement. Additionally, this study will be used to inform the future development of the rehabilitation game software as well as an optional game chair (in patients that use wheelchairs, the games can also be played from the patient's own chair).

To optimize the evaluation of these RePlay devices and software, and to decrease the time requirement for patients, research will be divided into two phases. Patients can participate in either one or both phases. Participation in phase II is not contingent on participation in phase I.

Phase I will involve 80 participants using the RePlay devices and games on a single visit. These 80 participants will be a collection of participants with no neurological disorders, participants recovering from stroke, those with Multiple Sclerosis, Parkinson's Disease and Spinal Cord Injuries. This will allow us to determine the ability of these patient populations to enjoyably use these devices and games compared with their degree of impairment. Participants' degree of impairment will be quantified by standard rehabilitation measurements for each disease process, including the ASIA Spinal Cord Impairment Scale, GRASSP, Jebsen Taylor Hand Function, dynomometry strength readings

In Phase II, 20 participants will be randomized equally to one of two groups. Each group will receive the same amount of therapy, only in a different sequence.

Group 1 will receive:

1. two weeks of RePlay device therapy twice per week at REACT (weeks 1-2), followed by re-assessment,

2. then will rest for 2 weeks (weeks 3-4),

3. then will take the RePlay devices and tablets home for two weeks (weeks 5-6) for daily RePlay device therapy, followed by re-assessment.

Group 2 will receive:

1. two weeks of RePlay device therapy daily at home (they will take the devices and tablets home) (weeks 1-2), followed by re-assessment,

2. then will rest for 2 weeks (weeks 3-4),

3. then will receive two weeks of RePlay device therapy twice per week at REACT (weeks 5-6), and then will undergo re-assessment.

This will allow investigators to test the Replay rehabilitation software and hardware over 2 two week periods in order to evaluate the pattern of game play improvement in this population over time in different settings.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: April 30, 2018
• Est. primary completion date: April 30, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Partial upper limb impairment in one or both arms as a result of a neurological injury or disease

• Age 18-65

Exclusion Criteria:

• Emotional disability that would interfere with participation as determined by Dr.

Wigginton

• Inability to understand instructions in English

• No upper limb movement

• Incarcerated individuals

• For Phase II, anticipated inability to complete study visits

Related Conditions & MeSH terms

• Spinal Cord Injuries

Intervention

Other:
• Physical exam and medical history
This will be completed by a medical doctor on the research team

Diagnostic Test:
• Assessments
One assessment in Phase I, and three assessments in Phase II (baseline, and following each 2 week active study period)

Device:
• Patient Instruction and use of Device (RePlay)
providing measurable upper extremity movement, control, and coordination feedback for patients, therapists, and physicians improving assessment and evaluation of patients involved in future interventional studies, producing a dynamic, responsive, inexpensive physical therapy system that can be used in the comfort of the participants' own home.

Locations

Country	Name	City	State
United States	REACT	Addison	Texas
United States	UT Dallas	Richardson	Texas

Sponsors (1)

Lead Sponsor	Collaborator
The University of Texas at Dallas

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the rehabilitation device design as reported by subjects using a 10-point Likert scale	Assess feasibility, ease of use and enjoyment for device in injured population. This will be measured by subject report. Subjects will verbally provide feedback as they use the software and hardware. Feedback will be recorded and changes will be made based on feedback received from participants. Subjects self-report their experienced enjoyment of RePlay using a 10-point Likert scale (10 = extreme enjoyment, 1 = no enjoyment). Higher scores represent a greater degree of experienced enjoyment.	Through Study Completion, approximately 8-9 weeks
Primary	Evaluate the functionality of rehabilitation device as reported by subjects using a 10-point Likert scale	Assess general fit, and functionality of these devices to further the device development. both in the home and in the rehabilitation setting. This will be measured by subject report. This will be measured by subject report. Subjects will verbally provide feedback as they use the software and hardware. Feedback will be recorded and changes will be made based on feedback received from participants. Subjects self-report their experienced fit and function of RePlay using a 10-point Likert scale (10 = extremely easy to fit, 1 = didn't fit at all). Higher scores represent a greater degree of experienced fit and function	Through Study Completion approximately 8-9 weeks